New Search

Advanced search
Export article
Open Access

Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis

Yoichiro Sugizaki, Hiromasa Otake, Koji Kuroda, Hiroyuki Kawamori, Takayoshi Toba, Akira Nagasawa, Ryo Takeshige, Shinsuke Nakano, Yoichiro Matsuoka, Kosuke Tanimura, Yu Takahashi, Yusuke Fukuyama, Ken-Ichi Hirata
Published: 5 August 2020
Circulation Journal ; doi:10.1253/circj.cj-20-0199

Abstract: Background:In-stent neoatherosclerosis (NA) is a risk for future cardiovascular events through atherosclerotic progression in non-stented lesions. Using optical coherence tomography, this study assessed the efficacy of intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA) vs. standard 2.5 mg/day rosuvastatin therapy on native coronary plaques in patients with NA. Methods and Results:This was a subgroup analysis of the randomized LINK-IT trial, which was designed to compare changes in the lipid index in NA between intensive and standard therapy for 12 months. In all, 42 patients with native coronary plaques and NA were assessed. Compared with standard therapy, intensive therapy resulted in greater decreases in serum low-density lipoprotein cholesterol concentrations and greater increases in serum 18-hydroxyeicosapentaenoic acid concentrations, with significantly greater decreases in the lipid index and macrophage grade in both NA (−24 vs. 217 [P
Keywords: Macrophage / Efficacy / stent / Grade / plaques / mg/day / Native Coronary

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "Circulation Journal" .
Back to Top Top